See Anoro Ellipta’s head-to-head data
Anoro Ellipta is the only LAMA/LABA with head-to-head data vs. a LAMA²⁻⁵ and vs. two LAMA/LABAs.⁶ ⁷
This is a fictional patient for illustrative purposes.
Anoro Ellipta is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.1
Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
© 2021 GSK group of companies or its licensor. ANORO was developed in collaboration with INNOVIVA.
Trademarks are owned by or licensed to the GSK group of companies.
PM-GB-UCV-WCNT-200034 May 2021